Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Hierarchically Positioning Laparoscopic Microwave Ablation in the Therapeutic Span of Early Hepatocellular Carcinoma: A Real-Life Comparative Analysis.
Ann Surg Oncol
February 2025
Unit of Hepato-biliary Surgery, Unit of General Surgery, ASST Fatebenefratelli Sacco, Milan, Italy.
Article Synopsis
- * A study involving nearly 2,000 non-resectable HCC patients showed that LMWA had comparable safety and overall survival rates to PRFA and significantly better survival rates than TACE after 1, 3, and 5 years.
- * The results suggest that LMWA is a viable treatment option for early HCC, outperforming TACE while demonstrating similar efficacy to PRFA, which supports its potential inclusion in standardized treatment
Myosteatosis is closely associated with sarcopenia and significantly worse outcomes in patients with cirrhosis.
J Hepatol
October 2024
Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy. Electronic address:
Article Synopsis
- The study examines muscle changes, specifically sarcopenia and myosteatosis, in cirrhosis patients to understand their prevalence and impact on health over a year.
- In a group of 433 patients, different combinations of these muscle changes were found, with notable increases in mortality and hospitalization rates linked to isolated myosteatosis and combined muscle changes.
- Findings indicate that both myosteatosis and sarcopenia are common in cirrhosis, leading to worse health outcomes, emphasizing the need for better prognostic evaluations in these patients.
Liver Resection vs Nonsurgical Treatments for Patients With Early Multinodular Hepatocellular Carcinoma.
JAMA Surg
August 2024
Department of General and Transplant Surgery, Grande Ospedale Metropolitano Niguarda, School of Medicine and Surgery, University of Milan-Bicocca, Milan, Italy.
Article Synopsis
- The 2022 Barcelona Clinic Liver Cancer algorithm advises against liver resection for patients with multiple small tumors (2 or 3 nodules, each ≤3 cm) in hepatocellular carcinoma.
- This study retrospectively analyzed data from over 12,000 patients to compare survival outcomes among those undergoing liver resection (LR), percutaneous radiofrequency ablation (PRFA), and transarterial chemoembolization (TACE).
- Results showed that LR had the highest survival rates at 1, 3, and 5 years (89.11%, 70.98%, 56.44% respectively) compared to PRFA and TACE, indicating that LR may offer better long-term outcomes in treating early multin
Prediction of cardiovascular risk in patients with hepatocellular carcinoma receiving anti-angiogenic drugs: lessons from sorafenib.
Intern Emerg Med
June 2024
Department of Medical and Surgical Sciences, University of Bologna, 40138, Bologna, Italy.
Antiangiogenics are associated with an increased risk of major adverse cardiac and cerebrovascular events (MACE). The identification of at-risk subjects is relevant in the case of hepatocellular carcinoma (HCC), for which anti-angiogenic TKIs and bevacizumab are used in first and subsequent lines of therapy, to select alternative drugs for patients with excessive risk. We verified the ability to predict MACE in sorafenib-treated patients of the 2022 European Society of Cardiology (ESC-2022) score for anti-angiogenics and the recently proposed CARDIOSOR score.
View Article and Find Full Text PDFBackground & Aims: Chronic hepatitis D virus (HDV) often leads to end-stage liver disease and hepatocellular carcinoma (HCC). Comprehensive data pertaining to large populations with HDV and HCC are missing, therefore we sought to assess the characteristics, management, and outcome of these patients, comparing them to patients with hepatitis B virus (HBV) infection.
Methods: We analysed the Italian Liver Cancer database focusing on patients with positivity for HBV surface antigen and anti-HDV antibodies (HBV/HDV, n = 107) and patients with HBV infection alone (n = 588).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!